Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation

被引：0

作者：

Patel, S. ^{[1
]}

Zhao, S. ^{[2
]}

Wei, L. ^{[2
]}

Li, M. ^{[3
]}

Bertino, E. ^{[3
]}

Presley, C. ^{[3
]}

Welliver, M. ^{[3
]}

Haglund, K. ^{[3
]}

Palmer, J. ^{[3
]}

Arnett, A. ^{[3
]}

Beyer, S. ^{[3
]}

Mende, E. ^{[3
]}

Elder, J. ^{[3
]}

Hardesty, D. ^{[3
]}

Shields, P. ^{[4
]}

Carbone, D. ^{[4
]}

Otterson, G. ^{[4
]}

Williams, T. ^{[3
]}

Owen, D. ^{[4
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Hematol Med Oncol, Columbus, OH 43210 USA

[2] Ohio State Univ, Ctr Comprehens Canc, Biostat, Columbus, OH 43210 USA

[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[4] Ohio State Univ, Ctr Comprehens Canc, Med Oncol, Columbus, OH 43210 USA

来源：

关键词：

Stage III NSCLC; Brain Metastasis; Durvalumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P21.02

引用

页码：S363 / S364

页数：2